Literature DB >> 16033272

Synthesis and structure-activity relationships of a new series of retinoid-related biphenyl-4-ylacrylic acids endowed with antiproliferative and proapoptotic activity.

Raffaella Cincinelli1, Sabrina Dallavalle, Raffaella Nannei, Serena Carella, Daniele De Zani, Lucio Merlini, Sergio Penco, Enrico Garattini, Giuseppe Giannini, Claudio Pisano, Loredana Vesci, Paolo Carminati, Valentina Zuco, Chiara Zanchi, Franco Zunino.   

Abstract

Atypical retinoids (AR) represent a class of proapoptotic agents with promising potential in the treatment of neoplastic diseases. In the present work 4'-hydroxybiphenyl-4-ylacrylic acids were studied as a novel series of AR. The synthesized compounds were evaluated for their antiproliferative activity in a human promyelocytic leukemia cell line (NB4) and in an ovarian carcinoma cell system including IGROV-1, carrying a functional wild-type p53, and a cisplatin-resistant subline, IGROV-1/Pt-1. The presence of a bulky lipophilic group at position 3' (adamantan-1-yl being the best) and the E configuration of the acrylic moiety appear essential for activity below 1 muM. No substitution on the rings or on the double bond improved the activity. A qualitative correlation between the log P and molecular volume of the 3'-substituent and the antiproliferative activity was found. From the study of a few selected compounds, it appears that the presence of the carboxylic group is an essential requirement for apoptogenic properties but not for antiproliferative activity, this being maintained in amide derivatives. On the other hand, compounds able to induce apoptosis produced a detectable level of genotoxic damage. This observation supports the hypothesis that the genotoxic stress is a critical event mediating apoptosis induction by compounds of this class. Among the compounds investigated, E-3-(3'-adamantan-1-yl-4'-hydroxybiphenyl-4-yl)acrylic acid (2) was chosen for further investigation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16033272     DOI: 10.1021/jm049440h

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  11 in total

1.  Design and synthesis of novel derivatives of all-trans retinoic acid demonstrate the combined importance of acid moiety and conjugated double bonds in its binding to PML-RAR-alpha oncogene in acute promyelocytic leukemia.

Authors:  Carolina Schinke; Swati Goel; Tushar D Bhagat; Li Zhou; Yongkai Mo; Robert Gallagher; George W Kabalka; Leonidas C Platanias; Amit Verma; Bhaskar Das
Journal:  Leuk Lymphoma       Date:  2010-06

2.  Highly twisted adamantyl arotinoids: synthesis, antiproliferative effects and RXR transactivation profiles.

Authors:  Santiago Pérez-Rodríguez; Maria A Ortiz; Raquel Pereira; Fátima Rodríguez-Barrios; Angel R de Lera; F Javier Piedrafita
Journal:  Eur J Med Chem       Date:  2009-01-20       Impact factor: 6.514

3.  Maximal adamantyl-substituted retinoid-related molecule-induced apoptosis requires NF-κB noncanonical and canonical pathway activation.

Authors:  L Farhana; M I Dawson; F Murshed; J A Fontana
Journal:  Cell Death Differ       Date:  2010-07-30       Impact factor: 15.828

Review 4.  The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

Authors:  Lukas Wanka; Khalid Iqbal; Peter R Schreiner
Journal:  Chem Rev       Date:  2013-02-25       Impact factor: 60.622

5.  Synthesis and characterization of poly(ε-caprolactone)-block-poly[N-(2-hydroxypropyl)methacrylamide] micelles for drug delivery.

Authors:  Stefan G Krimmer; Huaizhong Pan; Jihua Liu; Jiyuan Yang; Jindřich Kopeček
Journal:  Macromol Biosci       Date:  2011-05-12       Impact factor: 4.979

6.  Structure-Activity Relationship and Anticancer Profile of Second-Generation Anti-MRSA Synthetic Retinoids.

Authors:  Ana V Cheng; Wooseong Kim; Iliana E Escobar; Eleftherios Mylonakis; William M Wuest
Journal:  ACS Med Chem Lett       Date:  2019-07-17       Impact factor: 4.345

7.  Insights into the binding mode and mechanism of action of some atypical retinoids as ligands of the small heterodimer partner (SHP).

Authors:  Marco Cellanetti; Viswanath Gunda; Li Wang; Antonio Macchiarulo; Roberto Pellicciari
Journal:  J Comput Aided Mol Des       Date:  2010-09-30       Impact factor: 3.686

8.  An adamantyl-substituted retinoid-derived molecule that inhibits cancer cell growth and angiogenesis by inducing apoptosis and binds to small heterodimer partner nuclear receptor: effects of modifying its carboxylate group on apoptosis, proliferation, and protein-tyrosine phosphatase activity.

Authors:  Marcia I Dawson; Zebin Xia; Gang Liu; Mao Ye; Joseph A Fontana; Lulu Farhana; Bhamik B Patel; Sankari Arumugarajah; Mohammad Bhuiyan; Xiao-Kun Zhang; Young-Hoon Han; William B Stallcup; Jun-ichi Fukushi; Tomas Mustelin; Lutz Tautz; Ying Su; Danni L Harris; Nahid Waleh; Peter D Hobbs; Ling Jong; Wan-Ru Chao; Leonard J Schiff; Brahma P Sani
Journal:  J Med Chem       Date:  2007-05-10       Impact factor: 7.446

9.  Adamantyl-substituted retinoid-derived molecules that interact with the orphan nuclear receptor small heterodimer partner: effects of replacing the 1-adamantyl or hydroxyl group on inhibition of cancer cell growth, induction of cancer cell apoptosis, and inhibition of SRC homology 2 domain-containing protein tyrosine phosphatase-2 activity.

Authors:  Marcia I Dawson; Zebin Xia; Tao Jiang; Mao Ye; Joseph A Fontana; Lulu Farhana; Bhaumik Patel; Li Ping Xue; Mohammad Bhuiyan; Roberto Pellicciari; Antonio Macchiarulo; Roberto Nuti; Xiao-Kun Zhang; Young-Hoon Han; Lutz Tautz; Peter D Hobbs; Ling Jong; Nahid Waleh; Wan-Ru Chao; Gen-Sheng Feng; Yuhong Pang; Ying Su
Journal:  J Med Chem       Date:  2008-08-30       Impact factor: 7.446

10.  Ion-exchange-resin-catalyzed adamantylation of phenol derivatives with adamantanols: Developing a clean process for synthesis of 2-(1-adamantyl)-4-bromophenol, a key intermediate of adapalene.

Authors:  Nan Wang; Ronghua Wang; Xia Shi; Gang Zou
Journal:  Beilstein J Org Chem       Date:  2012-02-08       Impact factor: 2.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.